In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prof. Axel Ullrich: The New--Realistic--Biotech Era

Executive Summary

Perhaps Europe's leading academic entrepreneur, professor Axel Ullrich, PhD, joined Genentech in its infancy, then, returning to Germany as a director of the Max-Planck Institute, swam against a generally anti-commercial tide within the German academic community by founding Sugen and several German start-ups, most recently, U3 Pharma. He describes the aftermath of Germany's BioRegio program and a new dose of realism in European biotech.

You may also be interested in...



Market Access After COVID-19: Sector Goodwill Or Hard Crackdown?

The pandemic has brightened pharma’s image, but drug pricing is still high on the political agenda. For US and European politicians, the health crisis has heightened the tension between supporting innovation and controlling rising costs.

Pandemic Spotlights Tensions Between Profit And Philanthropy

The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.

Virtual Health Care: Where Does This Leave Pharma Marketing?

COVID-19 has triggered a dramatic shift toward virtual consultations and telemedicine, encouraged by more relaxed regulations and payer support.

Topics

Related Deals

UsernamePublicRestriction

Register

IV004742

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel